Company intelligence / Profile preview
HotSpot Therapeutics
Cambridge, Massachusetts, United Stateshotspotthera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
HotSpot Therapeutics has advanced its lead program HST–1011—a novel allosteric inhibitor of CBL-B—into Phase 1 clinical trials with first-in-human data presented at ESMO Congress in September 2024. The company also has preclinical programs targeting IRF5 for autoimmune disorders and MALT1 for hematologic malignancies and solid tumors. Its approach enables the targeting of previously undruggable proteins by exploiting natural regulatory “hotspots” using proprietary allosteric chemistry.
- Therapeutic areas
- OncologyMetabolic DisordersRheumatology
- Modalities
- small molecules (allosteric inhibitors)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on HotSpot Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HotSpot Therapeutics.